U.S. Health Agencies Allocated an Additional $884M for H1N1 flu vaccines

U.S. Congress Approves More Money Into H1N1 Pandemic Preparation

An additional $884 million in funding has been allocated to buy more ingredients an antigen and an adjuvant for swine flu vaccines. This is in addition to the $1 billion The Department of Health and Human Services committed to fighting the Swine Flu in May.

Novartis will get the bulk of the $884 million. The drugmaker has landed $690.1 million to produce bulk vaccine antigen as well as other ingredients. GlaxoSmithKline is being furnished with $71.4 million for bulk oil and water adjuvant, while Sanofi Pasteur will receive $61.4 million to produce ingredients.

Washington Business Journal writer, Vandana Sinha  reported that one month after (H1N1) swine flu was declared a global pandemic, MedImmune has been awarded additional $61 million contract from the U.S. Department of Health and Human Services, six weeks after it accepted a $90 million contract from the agency to manufacture ingredients for a potential vaccine for the H1N1 virus to fight the predicted Swine Flu outbreak.

MedImmune, now the Gaithersburg subsidiary of the London-based AstraZeneca PLC, is using the funding to produce and test the flu-fighting technology it uses in its seasonal FluMist product (nasal spray) as a viable treatment for the for the H1N1 virus.

The World Health Organization (WHO) has raised the H1N1 (Swine) Flu to the highest warning levels on the pandemic scale.

The follow-up awards were given to four of five pharmaceuticals that the federal government has been contracting with to produce potential vaccine materials — Sanofi Pasteur SA, GlaxoSmithKline PLC, Novartis AG, CSL Ltd. and MedImmune.

In all, the agency has spent nearly $1.9 billion to date on these contracts., MedImmune’s combined $150 million in awards have been the smallest so far of those companies.

Read Full Washington Business Journal Article
Read AP Story


Author: H. Sandra Chevalier-Batik

I started the Inconvenient Woman Blog in 2007, and am the product of a long line of inconvenient women. The matriarchal line is French-Canadian, Roman Catholic, with a very feisty Irish great-grandmother thrown in for sheer bloody mindedness. I am a research analyst and author who has made her living studying technical data, and developing articles, training materials, books and web content. Tracking through statistical data, and oblique cross-references to find the relevant connections that identifies a problem, or explains a path of action, is my passion. I love clearly delineating the magic questions of knowledge: Who, What, Why, When, Where and for How Much, Paid to Whom. My life lessons: listen carefully, question with boldness, and personally verify the answers. I look at America through the appreciative eyes of an immigrant, and an amateur historian; the popular and political culture is a ceaseless fascination. I have no impressive initials after my name. I’m merely an observer and a chronicler, an inconvenient woman who asks questions, and sometimes encourages others to look at things differently.